London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Nano laser photofragmentation: first results of a randomized clinical trial

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Cataract: Special Cases

Session Date/Time: Monday 15/09/2014 | 17:00-18:30

Paper Time: 17:45

Venue: Boulevard B

First Author: : G.Sauder GERMANY

Co Author(s): :    S. Hohn   E. Ruf           

Abstract Details

Purpose:

Comparison between standard Phakoemulsifikation and Nano Laser Photofragmentation in a randomised , prospective clinical trial with regard to the amount of surgical trauma

Setting:

Charlottenklinik

Methods:

60 patients were randomely distributed in a Nano Laser (NL) and a phako group (PH). Routine cataract surgery was performed by one experienced surgeon under topical anesthesia. Density of the cristaline lens was preoperatively staged according to the LOCS grade system – limitation of nuclear density was limited to +3. Main outcome measurements were pachymetry and endothelial cell count. Duration of surgery and infusion in ml per surgery were measured.

Results:

Duration of surgery was 5.14 min (PH) and 7.26 min in the NL group. The use of BSS was 25% higher in the NL group. The decrease in pachymetry at day 1 was 36.4 ± 30.2µm (PH) and 24.2 ± 18.0 µm (NLP). There was no significant difference in both groups concerning increase of visual acuity, postoperative IOP and complications

Conclusions:

The Nano Laser photofragmentation is a safe surgical technique with very low emission of energy into the eye. Positive results of the nano laser group compared to phako with regard to pachymetry and endothelial cell count has to be proved in more patients and in longer follow up period.

Financial Interest:

NONE

Back to previous